These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31222512)

  • 21. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
    Brzozowska A; Toruń A; Mazurkiewicz M
    Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infarct volume after glioblastoma surgery as an independent prognostic factor.
    Bette S; Wiestler B; Kaesmacher J; Huber T; Gerhardt J; Barz M; Delbridge C; Ryang YM; Ringel F; Zimmer C; Meyer B; Boeckh-Behrens T; Kirschke JS; Gempt J
    Oncotarget; 2016 Sep; 7(38):61945-61954. PubMed ID: 27566556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma.
    Zemskova O; Yu NY; Leppert J; Rades D
    Anticancer Res; 2024 Jul; 44(7):3059-3066. PubMed ID: 38925836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for glioblastoma therapy associated complications.
    Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
    Clin Neurol Neurosurg; 2015 Jul; 134():55-9. PubMed ID: 25942630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.
    Yang P; Wang Y; Peng X; You G; Zhang W; Yan W; Bao Z; Wang Y; Qiu X; Jiang T
    J Neurooncol; 2013 Jun; 113(2):259-66. PubMed ID: 23483435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Indicators of Systemic Inflammatory Response on Survival in Glioblastoma Multiforme.
    Mermut O; Inanc B
    Turk Neurosurg; 2020; 30(5):658-665. PubMed ID: 32530473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
    Comas S; Luguera E; Molero J; Balaña C; Estival A; Castañer S; Carrato C; Hostalot C; Teixidor P; Villà S
    Clin Transl Oncol; 2021 Mar; 23(3):554-564. PubMed ID: 32728970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
    Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
    J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
    Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
    PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body mass index as an independent prognostic factor in glioblastoma.
    Valente Aguiar P; Carvalho B; Vaz R; Linhares P
    Cancer Causes Control; 2021 Apr; 32(4):327-336. PubMed ID: 33447892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.